In the frame of a research program aimed to explore the relationship between chirality of iminosugars and their therapeutic potential, herein we report the synthesis of N-akyl L-deoxyiminosugars and the evaluation of the anti-inflammatory properties of selected candidates for the treatment of Pseudomonas aeruginosa infections in Cystic Fibrosis (CF)lung disease. Target glycomimetics were prepared by the shortest and most convenient approach reported to date, relying on the use of the well-known PS-TPP/I 2 reagent system to prepare reactive alkoxyalkyl iodides, acting as key intermediates. Iminosugars ent-1-3 demonstrated to efficiently reduce the inflammatory response induced by P. aeruginosa in CuFi cells, either alone or in synergistic combination with their D-enantiomers, by selectively inhibiting NLGase. Surprisingly, the evaluation in murine models of lung disease showed that the amount of ent-1 required to reduce the recruitment of neutrophils was 40-fold lower than that of the corresponding D-enantiomer. The remarkably low dosage of the L-iminosugar, combined with its inability to act as inhibitor for most glycosidases, is expected to limit the onset of undesired effects, which are typically associated with the administration of its D-counterpart. Biological results herein obtained place ent-1 and congeners among the earliest examples of L-iminosugars acting as anti-inflammatory agents for therapeutic applications in Cystic Fibrosis.

Exploring the effect of chirality on the therapeutic potential of N-alkyl-deoxyiminosugars: anti-inflammatory response to Pseudomonas aeruginosa infections for application in CF lung disease / M. De Fenza, D. D'Alonzo, A. Esposito, S. Munari, N. Loberto, A. Santangelo, I. Lampronti, A. Tamanini, A. Rossi, S. Ranucci, I. De Fino, A. Bragonzi, M. Aureli, R. Bassi, M. Tironi, G. Lippi, R. Gambari, G. Cabrini, G. Palumbo, M.C. Dechecchi, A. Guaragna. - In: EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY. - ISSN 0223-5234. - 175(2019 Aug 01), pp. 63-71.

Exploring the effect of chirality on the therapeutic potential of N-alkyl-deoxyiminosugars: anti-inflammatory response to Pseudomonas aeruginosa infections for application in CF lung disease

N. Loberto;M. Aureli;R. Bassi;G. Lippi;G. Cabrini;
2019

Abstract

In the frame of a research program aimed to explore the relationship between chirality of iminosugars and their therapeutic potential, herein we report the synthesis of N-akyl L-deoxyiminosugars and the evaluation of the anti-inflammatory properties of selected candidates for the treatment of Pseudomonas aeruginosa infections in Cystic Fibrosis (CF)lung disease. Target glycomimetics were prepared by the shortest and most convenient approach reported to date, relying on the use of the well-known PS-TPP/I 2 reagent system to prepare reactive alkoxyalkyl iodides, acting as key intermediates. Iminosugars ent-1-3 demonstrated to efficiently reduce the inflammatory response induced by P. aeruginosa in CuFi cells, either alone or in synergistic combination with their D-enantiomers, by selectively inhibiting NLGase. Surprisingly, the evaluation in murine models of lung disease showed that the amount of ent-1 required to reduce the recruitment of neutrophils was 40-fold lower than that of the corresponding D-enantiomer. The remarkably low dosage of the L-iminosugar, combined with its inability to act as inhibitor for most glycosidases, is expected to limit the onset of undesired effects, which are typically associated with the administration of its D-counterpart. Biological results herein obtained place ent-1 and congeners among the earliest examples of L-iminosugars acting as anti-inflammatory agents for therapeutic applications in Cystic Fibrosis.
L-Deoxyiminosugars; L-NBDNJ; Cystic fibrosis; Polymeric triphenylphosphine; NLGase; Agiwpluwfdfejs-Uhfffaoysa-N; Anootoptcjrupk-Uhfffaoysa-N; Cystic Fibrosis; Ftscegkykxesff-Lxtvhrrpsa-N; Ftscegkykxesff-Xgubffrzsa-N; Gpdcqnbejwtad-Uhfffaoysa-N; Iaeoyuupfyjxhn-Uhfffaoysa-N; Inkbdaikckxose-Uhfffaoysa-N; Kihgpsmgduhoiv-Uhfffaoysa-N; L-Deoxyiminosugars; L-Nbdnj; Lxbifeviblougu-Fsiimwslsa-N; Mdvgooianlzfcp-Uhfffaoysa-N; Nlgase; Nutsediynmvymt-Uhfffaoysa-N; Ogsjmfcwouhxhn-Uhfffaoysa-N; Polymeric Triphenylphosphine; Rcjyhjgghwfotn-Uhfffaoysa-N; Rcxjpsznthetpe-Yvsfhvdlsa-N; Rcxjpsznthetpe-Yyiausfcsa-N; Sxpluakszjtqbc-Iywmvgaksa-N; Sxpluakszjtqbc-Yrpnkdgesa-N; Uqrorfvvsgfnro-Jxuboqscsa-N; Uqrorfvvsgfnro-Utinfbmnsa-N; Wwfjfhugmyykef-Uhfffaoysa-N; Xvylnhveaooegi-Faiwkwdxsa-N; Xvylnhveaooegi-Ljnkjdijsa-N; Zsiaufguxnugdi-Uhfffaoysa-N; Zwruinpwmlaqrd-Uhfffaoysa-N; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Bronchi; Cystic Fibrosis; Dose-Response Relationship, Drug; Humans; Imino Sugars; Inflammation; Inhibitory Concentration 50; Mice; Neutrophils; Pseudomonas Infections; Pseudomonas Aeruginosa; Stereoisomerism; Beta-Glucosidase
Settore CHIM/06 - Chimica Organica
1-ago-2019
Article (author)
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S0223523419303794-main.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 1.11 MB
Formato Adobe PDF
1.11 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
RevMan_D'Alonzo_EurJMedChem.pdf

accesso aperto

Tipologia: Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione 1.2 MB
Formato Adobe PDF
1.2 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/662171
Citazioni
  • ???jsp.display-item.citation.pmc??? 11
  • Scopus 16
  • ???jsp.display-item.citation.isi??? 16
social impact